These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22264247)

  • 1. A novel form of amyloid deposited at the site of enfuvirtide injection.
    Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM
    J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247
    [No Abstract]   [Full Text] [Related]  

  • 2. Localized amyloidosis at the site of enfuvirtide injection.
    Morilla ME; Kocher J; Harmaty M
    Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777
    [No Abstract]   [Full Text] [Related]  

  • 3. [Enfuvirtide].
    Gerstoft J
    Ugeskr Laeger; 2004 Nov; 166(48):4355-7. PubMed ID: 15587625
    [No Abstract]   [Full Text] [Related]  

  • 4. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfuvirtide: a new class of antiretroviral therapy for HIV infection.
    Leao JC; Frezzini C; Porter S
    Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse of intravenous drug use triggered by enfuvirtide, a parenteral antiretroviral medication.
    Avelino-Silva VI; Li HY; Novaes CT
    AIDS Patient Care STDS; 2012 Feb; 26(2):71-2. PubMed ID: 22148866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New partnership calls for clinical testing of two fusion inhibitors.
    Slovick J
    Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078
    [No Abstract]   [Full Text] [Related]  

  • 11. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    Oates E; Dzintars K
    Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious infection from Staphylococcus aureus in 2 HIV-infected patients receiving fusion inhibitor therapy.
    Gaughan EM; Ritter ML; Kumar PN; Timpone JG
    AIDS Read; 2008 May; 18(5):266-8. PubMed ID: 18589482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL
    Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
    Allavena C; Prazuck T; Reliquet V; Verdon R; Perré P; Le Moal G; Billaud E; Raffi F
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):187-92. PubMed ID: 18599881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction.
    Shahar E; Moar C; Pollack S
    AIDS; 2005 Mar; 19(4):451-2. PubMed ID: 15750403
    [No Abstract]   [Full Text] [Related]  

  • 17. [Entry inhibitors. Ring-free for a new principle of action].
    Rümmelein N; Jäger H
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():16-20. PubMed ID: 15011578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide.
    Quiros-Roldan E; Tirelli V; Torti C; Sosta E; Tosoni C; Damiolini E; Carosi G
    AIDS; 2007 Jun; 21(10):1388-9. PubMed ID: 17545726
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.
    Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A
    New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
    Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
    AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.